Historical perspectives and guidelines for botulinum neurotoxin subtype nomenclature, Toxins, vol.9, 2017. ,
URL : https://hal.archives-ouvertes.fr/pasteur-01821691
, Clin. Infect. Dis, vol.41, pp.1167-1173, 2005.
Botulism symptoms, incubation period and complications, diagnosis and management. In Clostridium Botulinum: A Spore Forming Organism and a Challenge to Food Safety; Advances in Food Safety and Food Microbiology, 2012. ,
The occurrence of clostridium botulinum at aquatic sites in and around auckland and other urban areas of the North Island, N. Z. Vet. J, vol.30, pp.110-112, 1982. ,
Bacterial toxins: A table of lethal amounts, Microbiol. Rev, vol.46, pp.86-94, 1982. ,
Molecular architecture of botulinum neurotoxin e revealed by single particle electron microscopy, J. Biol. Chem, vol.283, pp.3997-4003, 2008. ,
Botulinum toxin as a biological weapon: Medical and public health management, JAMA, vol.285, pp.1059-1070, 2001. ,
Former Soviet Biological Weapons Facilities in Kazakhstan: Past, Present, and Future; Monterey Institute of International Studies, 1999. ,
Analyzing a bioterror attack on the food supply: The case of botulinum toxin in milk, Proc. Natl. Acad. Sci, vol.102, pp.9984-9989, 2005. ,
Two cases of food-borne botulism in Finland caused by conserved olives, vol.16, 2011. ,
In vitro characterization of botulinum toxin types A, C and D action on human tissues: Combined electrophysiologic, pharmacologic and molecular biologic approaches, J. Pharmacol. Exp. Ther, vol.280, pp.1489-1498, 1997. ,
Type F infant botulism: Investigation of recent clusters and overview of this exceedingly rare disease, Clin. Infect. Dis, vol.66, pp.92-94, 2017. ,
A novel strain of clostridium botulinum that produces type b and type h botulinum toxins, J. Infect. Dis, vol.209, pp.183-191, 2014. ,
A novel botulinum neurotoxin, previously reported as serotype h, has a hybrid-like structure with regions of similarity to the structures of serotypes a and f and is neutralized with serotype a antitoxin, J. Infect. Dis, vol.213, pp.379-385, 2016. ,
Validity of botulinum neurotoxin serotype h, J. Infect. Dis, vol.210, pp.992-993, 2014. ,
Botulinum neurotoxin homologs in non-clostridium species, FEBS Lett, vol.589, pp.342-348, 2015. ,
Identification and characterization of a novel botulinum neurotoxin, Nat. Commun, vol.8, 2017. ,
The first non clostridial botulinum-like toxin cleaves vamp within the juxtamembrane domain, Sci. Rep, vol.6, 2016. ,
Crystal structure of the catalytic domain of the weissella oryzae botulinum-like toxin, FEBS Lett, vol.593, pp.1403-1410, 2019. ,
Identification of a novel botulinum neurotoxin gene cluster in enterococcus, FEBS Lett, vol.592, pp.310-317, 2018. ,
Crystal structure of botulinum neurotoxin type a and implications for toxicity, Nat. Struct. Biol, vol.5, pp.898-902, 1998. ,
Domain organization in clostridium botulinum neurotoxin type e is unique: Its implication in faster translocation, J. Mol. Biol, vol.386, pp.233-245, 2009. ,
Structure and function of tetanus and botulinum neurotoxins, Q. Rev. Biophys, vol.28, pp.423-472, 1995. ,
Botulinum neurotoxin: A marvel of protein design, Annu. Rev. Biochem, vol.79, pp.591-617, 2010. ,
Entering neurons: Botulinum toxins and synaptic vesicle recycling, EMBO Rep, vol.7, pp.995-999, 2006. ,
The metallo-proteinase activity of tetanus and botulism neurotoxins, J. Physiol, vol.89, pp.43-50, 1995. ,
Botulinum neurotoxins: Biology, pharmacology, and toxicology, Pharm. Rev, vol.69, pp.200-235, 2017. ,
The ha proteins of botulinum toxin disrupt intestinal epithelial intercellular junctions to increase toxin absorption, Cell. Microbiol, vol.10, pp.355-364, 2008. ,
Botulinum hemagglutinin disrupts the intercellular epithelial barrier by directly binding e-cadherin, J. Cell Biol, vol.189, pp.691-700, 2010. ,
Botulinum toxin a complex exploits intestinal m cells to enter the host and exert neurotoxicity, Nat. Commun, vol.6, p.6255, 2015. ,
Translocation and dissemination to target neurons of botulinum neurotoxin type b in the mouse intestinal wall, Cell. Microbiol, vol.18, pp.282-301, 2016. ,
URL : https://hal.archives-ouvertes.fr/pasteur-01780625
Challenges in searching for therapeutics against botulinum neurotoxins, Expert Opin. Drug Discov, vol.12, pp.497-510, 2017. ,
Safety and immunogenicity of investigational recombinant botulinum vaccine, rbv a/b, in volunteers with pre-existing botulinum toxoid immunity, vol.36, pp.2041-2048, 2018. ,
Human botulism immune globulin for the treatment of infant botulism, N. Engl. J. Med, vol.354, pp.462-471, 2006. ,
Initial recovery and rebound of type f intestinal colonization botulism after administration of investigational heptavalent botulinum antitoxin, Clin. Infect. Dis, vol.53, pp.125-128, 2011. ,
Botulinum neurotoxin vaccines: Past history and recent developments, vol.5, pp.794-805, 2009. ,
Studies on immunity to toxins of clostridium botulinum. Ix. Immunologic response of man to purified pentavalent abcde botulinum toxiod, J. Immunol, vol.90, pp.697-702, 1963. ,
Development of vaccines for prevention of botulism, Biochimie, vol.82, pp.955-966, 2000. ,
Evaluation of neutralizing antibodies to type A, B, E, and F botulinum toxins in sera from human recipients of botulinum pentavalent (abcde) toxoid, J. Clin. Microbiol, vol.27, pp.1906-1908, 1989. ,
Characterization of new formalin-detoxified botulinum neurotoxin toxoids, Clin. Vaccine Immunol, vol.15, pp.1374-1379, 2008. ,
New equine antitoxins to botulinum neurotoxins serotypes a and b, Biologicals, vol.40, pp.240-246, 2012. ,
Retrospective survey to evaluate the safety and efficacy of japanese botulinum antitoxin therapy in japan, Toxicon, vol.110, pp.12-18, 2016. ,
, CDC. Investigational heptavalent botulinum antitoxin (hbat) to replace licensed botulinum antitoxin ab and investigational botulinum antitoxin E. Mmwr, p.299, 2010.
Question 1: In infant botulism, is equine-derived botulinum antitoxin (eqba) an effective alternative therapy to human-derived botulinum immune globulin (big)?, Arch. Dis. Child, vol.103, pp.907-909, 2018. ,
Sequence variation within botulinum neurotoxin serotypes impacts antibody binding and neutralization, Infect. Immun, vol.73, pp.5450-5457, 2005. ,
The european antibotabe framework program and its update: Development of innovative botulinum antibodies, Toxins, vol.9, 2017. ,
Isolation of antibodies from non-human primates for clinical use, Curr. Drug Discov. Technol, vol.11, pp.20-27, 2014. ,
Non-human primate immune libraries combined with germline humanization: An (almost) new, and powerful approach for the isolation of therapeutic antibodies, MAbs, vol.1, pp.377-381, 2009. ,
Antibody mapping to domains of botulinum neurotoxin serotype a in the complexed and uncomplexed forms, Infect. Immun, vol.65, pp.1626-1630, 1997. ,
Fine and domain-level epitope mapping of botulinum neurotoxin type a neutralizing antibodies by yeast surface display, J. Mol. Biol, vol.365, pp.196-210, 2007. ,
Epitope mapping of neutralizing botulinum neurotoxin a antibodies by phage display, Infect. Immun, vol.69, pp.6511-6514, 2001. ,
Mapping of the antibody-binding regions on the hn-domain (residues 449-859) of botulinum neurotoxin A with antitoxin antibodies from four host species. Full profile of the continuous antigenic regions of the h-chain of botulinum neurotoxin A, Protein J, vol.23, pp.39-52, 2004. ,
Submolecular recognition profiles in two mouse strains of non-protective and protective antibodies against botulinum neurotoxin A, Mol. Immunol, vol.42, pp.1509-1520, 2005. ,
Mapping of protective and cross-reactive domains of the type a neurotoxin of clostridium botulinum, vol.14, pp.1538-1544, 1996. ,
, Pharmacokinetics of human recombinant anti-botulinum toxin antibodies in rats. Toxins (Basel) 2019, vol.11
Efficient serum clearance of botulinum neurotoxin achieved using a pool of small antitoxin binding agents, Infect. Immun, vol.78, pp.756-763, 2010. ,
A natural human igm antibody that neutralizes botulinum neurotoxin in vivo, Hybridoma (Larchmt), vol.27, pp.65-69, 2008. ,
Hybridoma populations enriched for affinity-matured human iggs yield high-affinity antibodies specific for botulinum neurotoxins, J. Immunol. Methods, vol.333, pp.156-166, 2008. ,
Molecular recognition of botulinum neurotoxin b heavy chain by human antibodies from cervical dystonia patients that develop immunoresistance to toxin treatment, Mol. Immunol, vol.45, pp.3878-3888, 2008. ,
Regions of recognition by blocking antibodies on the light chain of botulinum neurotoxin a: Antigenic structure of the entire toxin, Immunobiology, vol.216, pp.698-706, 2011. ,
Molecular basis of immunogenicity to botulinum neurotoxins and uses of the defined antigenic regions, Toxicon, vol.107, pp.50-58, 2015. ,
Deciphering antibody properties that lead to potent botulinum neurotoxin neutralization, Mov. Disord, vol.19, pp.101-108, 2004. ,
Characterization of botulinum neurotoxin type a neutralizing monoclonal antibodies and influence of their half-lives on therapeutic activity, PLoS ONE, vol.5, 2010. ,
URL : https://hal.archives-ouvertes.fr/pasteur-01762095
Potent neutralization of botulinum neurotoxin by recombinant oligoclonal antibody, Proc. Natl. Acad. Sci, vol.99, pp.11346-11350, 2002. ,
Monoclonal antibodies that inhibit the proteolytic activity of botulinum neurotoxin serotype/b. Toxins (Basel), vol.7, pp.3405-3423, 2015. ,
A three monoclonal antibody combination potently neutralizes multiple botulinum neurotoxin serotype f subtypes, PLoS ONE, vol.12, 2017. ,
Monoclonal antibodies targeting the alpha-exosite of botulinum neurotoxin serotype/a inhibit catalytic activity, PLoS ONE, vol.10, 2015. ,
Neutralizing human monoclonal antibodies binding multiple serotypes of botulinum neurotoxin, Protein Eng. Des. Sel, vol.24, pp.321-331, 2011. ,
A three monoclonal antibody combination potently neutralizes multiple botulinum neurotoxin serotype e subtypes, Toxins (Basel, issue.10, p.105, 2018. ,
Evaluating the synergistic neutralizing effect of anti-botulinum oligoclonal antibody preparations, PLoS ONE, vol.9, p.87089, 2014. ,
Monoclonal antibodies to type a, b, e and f botulinum neurotoxins, Russ. J. Bioorganic Chem, vol.37, pp.344-353, 2011. ,
Sheep monoclonal antibodies prevent systemic effects of botulinum neurotoxin a1, Toxins (Basel), vol.2012, pp.1565-1581 ,
Extraction and inhibition of enzymatic activity of botulinum neurotoxins /b1, /b2, /b3, /b4, and /b5 by a panel of monoclonal anti-bont/b antibodies, BMC Biochem, vol.12, 2011. ,
Potent neutralization of botulinum neurotoxin/b by synergistic action of antibodies recognizing protein and ganglioside receptor binding domain, PLoS ONE, vol.7, 2012. ,
Monoclonal antibody combinations prevent serotype a and serotype b inhalational botulism in a guinea pig model, Toxins ,
Characterization of neutralizing mouse-human chimeric and shuffling antibodies against botulinum neurotoxin A, Microbiol. Immunol, vol.56, pp.748-755, 2012. ,
Production of a neutralizing mouse-human chimeric antibody against botulinum neurotoxin serotype E, Jpn. J. Infect. Dis, vol.66, pp.46-50, 2013. ,
Production and characterisation of a neutralising chimeric antibody against botulinum neurotoxin A, PLoS ONE, vol.5, 2010. ,
URL : https://hal.archives-ouvertes.fr/pasteur-01762123
Localization of the sites and characterization of the mechanisms by which anti-light chain antibodies neutralize the actions of the botulinum holotoxin, vol.27, pp.2616-2624, 2009. ,
Antibody protection against botulinum neurotoxin intoxication in mice, Infect. Immun, vol.77, pp.4305-4313, 2009. ,
Mechanisms of enhanced neutralization of botulinum neurotoxin by monoclonal antibodies conjugated to antibodies specific for the erythrocyte complement receptor, Mol. Immunol, vol.57, pp.247-254, 2014. ,
Rbc adherence of immune complexes containing botulinum toxin improves neutralization and macrophage uptake, Toxins, vol.9, p.173, 2017. ,
Enhanced neutralization potency of botulinum neurotoxin antibodies using a red blood cell-targeting fusion protein, PLoS ONE, vol.6, 2011. ,
Neutralization of botulinum neurotoxin by a human monoclonal antibody specific for the catalytic light chain, PLoS ONE, vol.3, 2008. ,
Identification of the factors that govern the ability of therapeutic antibodies to provide postchallenge protection against botulinum toxin: A model for assessing postchallenge efficacy of medical countermeasures against agents of bioterrorism and biological warfare, J. Pharmacol. Exp. Ther, vol.338, pp.503-517, 2011. ,
Design options for mrna-encoded bont antitoxins employing camelid single-domain antibody (vhh) components, Toxicon, vol.156, p.120, 2018. ,
Antigenic sites on the hn domain of botulinum neurotoxin a stimulate protective antibody responses against active toxin, Sci. Rep, vol.5, 2015. ,
Identification of the synaptic vesicle glycoprotein 2 receptor binding site in botulinum neurotoxin A, FEBS Lett, vol.588, pp.1087-1093, 2014. ,
Interaction between the two subdomains of the c-terminal part of the botulinum neurotoxin a is essential for the generation of protective antibodies, FEBS Lett, vol.572, pp.299-306, 2004. ,
Algal chloroplast produced camelid vh h antitoxins are capable of neutralizing botulinum neurotoxin, Plant. Biotechnol. J, vol.13, pp.117-124, 2015. ,
Camelid-derived heavy-chain nanobody against clostridium botulinum neurotoxin E in pichia pastoris, Biotechnol. Appl. Biochem, vol.63, pp.200-205, 2016. ,
Camelid single domain antibodies (vhhs) as neuronal cell intrabody binding agents and inhibitors of clostridium botulinum neurotoxin (bont) proteases, Toxicon, vol.56, pp.990-998, 2010. ,
Genetically engineered red cells expressing single domain camelid antibodies confer long-term protection against botulinum neurotoxin, Nat. Commun, vol.8, p.423, 2017. ,
Generation of high-titer neutralizing antibodies against botulinum toxins A, B, and E by DNA electrotransfer, Infect. Immun, vol.77, pp.2221-2229, 2009. ,
Egg yolk antibodies for detection and neutralization of clostridium botulinum type A neurotoxin, J. Food Prot, vol.72, pp.1005-1011, 2009. ,
DNA electroporation in rabbits as a method for generation of high-titer neutralizing antisera: Examples of the botulinum toxins types A, B, and E, Hum. Vaccin Immunother, vol.9, pp.2147-2156, 2013. ,
Phage libraries for generation of anti-botulinum scfv antibodies, Methods Mol. Biol, vol.145, pp.219-240, 2000. ,
Molecular characterization of murine humoral immune response to botulinum neurotoxin type a binding domain as assessed by using phage antibody libraries, Infect. Immun, vol.65, pp.3743-3752, 1997. ,
Genetic and immunological comparison of anti-botulinum type A antibodies from immune and non-immune human phage libraries, vol.20, pp.1640-1648, 2002. ,
Characterization of neutralizing antibodies and identification of neutralizing epitope mimics on the clostridium botulinum neurotoxin type A, Appl. Environ. Microbiol, vol.67, pp.3201-3207, 2001. ,
Selection and characterization of a human monoclonal neutralizing antibody for clostridium botulinum neurotoxin serotype B, Bioorganic Med. Chem. Lett, vol.19, pp.662-664, 2009. ,
Neutralizing antibodies of botulinum neurotoxin serotype A screened from a fully synthetic human antibody phage display library, J. Biomol. Screen, vol.14, pp.991-998, 2009. ,
Affinity maturation of human botulinum neurotoxin antibodies by light chain shuffling via yeast mating, Protein Eng. Des. Sel, vol.23, pp.311-319, 2010. ,
In vivo neutralization of botulinum neurotoxins serotype e with heavy-chain camelid antibodies (vhh), Mol. Biotechnol, vol.55, pp.159-167, 2013. ,
Immunological characterization and neutralizing ability of monoclonal antibodies directed against botulinum neurotoxin type H, J. Infect. Dis, vol.213, pp.1606-1614, 2016. ,
Purification and characterization of botulinum neurotoxin fa from a genetically modified clostridium botulinum strain, vol.1, 2016. ,
An ambient temperature-stable antitoxin of nine co-formulated antibodies for botulism caused by serotypes A, B and E, PLoS ONE, vol.13, 2018. ,
Safety and pharmacokinetics of xoma 3ab, a novel mixture of three monoclonal antibodies against botulinum toxin A, Antimicrob. Agents Chemother, vol.58, pp.5047-5053, 2014. ,
Botulism and vaccines for its prevention, Vaccine, vol.27, pp.33-39, 2009. ,
New and emerging indications of botulinum toxin therapy, Parkinsonism Relat. Disord, vol.17, pp.25-27, 2011. ,
The expanding therapeutic utility of botulinum neurotoxins, Toxins (Basel, vol.10, 2018. ,
An update on new and unique uses of botulinum toxin in movement disorders, Toxicon, vol.147, pp.84-88, 2018. ,
, Botulinum toxins as inhibitory probes and versatile therapeutics, vol.9, pp.326-335, 2009.
Clinical applications of botulinum toxin, Curr. Opin. Microbiol, vol.15, pp.325-336, 2012. ,
A brief history of neurological botulinum toxin therapy in germany, J. Neural Transm, vol.124, pp.1217-1221 ,
Differences in botulinum toxins: Time to end the confusion, J. Cosmet. Laser Ther, vol.11, pp.180-181, 2009. ,
Facing depression with botulinum toxin: A randomized controlled trial, J. Psychiatr. Res, vol.46, pp.574-581, 2012. ,
Botulinum toxin relieves anxiety and depression in patients with hemifacial spasm and blepharospasm, Neuropsychiatr. Dis. Treat, vol.15, pp.33-36, 2019. ,
Enhancing toxin-based vaccines against botulism, vol.36, pp.827-832, 2018. ,
Immunization of mice with the non-toxic hc50 domain of botulinum neurotoxin presented by rabies virus particles induces a strong immune response affording protection against high-dose botulinum neurotoxin challenge, vol.29, pp.4638-4645, 2011. ,
Efficacy of a potential trivalent vaccine based on hc fragments of botulinum toxins A, B, and E produced in a cell-free expression system, Clin. Vaccine Immunol, vol.17, pp.784-792, 2010. ,
Potent tetravalent replicon vaccines against botulinum neurotoxins using DNA-based semliki forest virus replicon vectors, vol.31, pp.2427-2432, 2013. ,
Pentavalent replicon vaccines against botulinum neurotoxins and tetanus toxin using DNA-based semliki forest virus replicon vectors, Hum. Vaccin Immunother, vol.10, pp.1874-1879, 2014. ,
Botulinum neurotoxin neutralizing activity of immune globulin (ig) purified from clinical volunteers vaccinated with recombinant botulinum vaccine (rbv a/b). Vaccine, vol.28, pp.7313-7318, 2010. ,
DNA vaccines targeting heavy chain c-terminal fragments of clostridium botulinum neurotoxin serotypes A, B, and E induce potent humoral and cellular immunity and provide protection from lethal toxin challenge, Hum. Vaccin Immunother, vol.11, 1961. ,
Baculoviral vector-mediated transient and stable transgene expression in human embryonic stem cells, Stem Cells, vol.25, pp.1055-1061, 2007. ,
Rapid immune responses to a botulinum neurotoxin hc subunit vaccine through in vivo targeting to antigen-presenting cells, Infect. Immun, vol.79, pp.3388-3396, 2011. ,
Sublingual immunization with adenovirus f protein-based vaccines stimulates protective immunity against botulinum neurotoxin a intoxication, Int. Immunol, vol.24, pp.117-128, 2012. ,
Clinical study of new tetravalent (type A, B, E, and F) botulinum toxoid vaccine derived from m toxin in japan, Jpn. J. Infect. Dis, vol.70, pp.423-429, 2017. ,
Recombinant botulinum neurotoxin hc subunit (bont hc) and catalytically inactive clostridium botulinum holoproteins (cibont hps) as vaccine candidates for the prevention of botulism, Toxins, vol.9, p.269, 2017. ,
A mutated recombinant subunit vaccine protects mice and guinea pigs against botulinum type A intoxication, Hum. Vaccin Immunother, vol.14, pp.329-336, 2018. ,
Reply: Comparison of steroid and botulinum toxin type a monotherapy with combination therapy for treating human hypertrophic scars in an animal model, Plast. Reconstr. Surg, vol.141, pp.452-453, 2018. ,